Myriad Genetics Inc. filings document the regulatory record of a molecular diagnostics and precision medicine company. Recent Form 8-K reports furnish quarterly and annual financial results, preliminary revenue and test-volume information, guidance, and product-related operating updates tied to Cancer Care Continuum, Prenatal Health, Mental Health, Precise MRD, and MyChoice CDx.
The company's proxy materials cover board matters, executive compensation, equity awards, and annual meeting governance. Other current reports document officer transitions, compensatory arrangements, and amendments to previously furnished earnings materials, providing formal disclosure of governance changes and financial-reporting corrections.
Myriad Genetics President and CEO Samraat S. Raha reported equity compensation and related tax withholding transactions in common stock. On March 12, 2026, he received a grant of 618,557 time-based restricted stock units, each representing one future share, vesting in three equal annual installments starting on the first anniversary of the grant date.
On March 13 and 14, 2026, a total of 47,120 shares of common stock were withheld by the company at $4.66 per share to cover tax obligations from previously vesting restricted stock units. After these transactions, Raha directly owns 1,064,541 shares of Myriad Genetics common stock.
Myriad Genetics President and CEO Samraat S. Raha reported an open-market purchase of 40,000 shares of common stock. The shares were bought at a weighted average price of $4.9961 per share in multiple trades between $4.97 and $5.00. Following this transaction, Raha directly owns 493,104 shares of Myriad Genetics common stock.
Myriad Genetics, Inc. registered a shelf to offer up to $200,000,000 of common stock, preferred stock, depositary shares, debt securities and/or warrants under a prospectus dated March 4, 2026.
The prospectus describes the types of securities that may be sold from time to time and states that specific terms, pricing and net proceeds for any issuance will be provided in an accompanying prospectus supplement. Common stock outstanding totaled 93,508,165 shares as of February 19, 2026.
Myriad Genetics Chief People Officer Shereen Solaiman reported a tax-related share withholding connected to vesting restricted stock units. On March 1, 2026, 1,675 shares of common stock were withheld at a price of $4.61 per share to cover tax obligations. After this tax-withholding disposition, Solaiman directly held 109,288 shares of Myriad Genetics common stock.
Myriad Genetics director S. Louise Phanstiel reported open‑market purchases of a total of 104,507 shares of common stock across three days. She bought 6,100 shares on February 25 at $4.736 per share, 50,407 shares on February 26 at $4.803 per share, and 48,000 shares on February 27 at $4.661 per share.
The reported prices are weighted averages for multiple trades executed within disclosed intraday ranges. After these transactions, she held 281,951 shares directly and 33,119 shares indirectly through The Phanstiel Trust.
Myriad Genetics is registering up to $200,000,000 of securities for sale from time to time. This shelf prospectus, dated February 24, 2026, covers common stock, preferred stock, depositary shares, debt securities and warrants that the company may offer in one or more offerings.
The prospectus explains that specific terms, prices and underwriting arrangements will be provided in future prospectus supplements, and that proceeds from any sales are expected to be used for general corporate purposes, including operations, R&D, possible debt repayment and acquisitions.
Myriad Genetics outlines its 2025 business strategy and operations in oncology, women’s health, and mental health, centered on molecular diagnostics and precision medicine. The company emphasizes hereditary cancer testing, prenatal screening, and the GeneSight pharmacogenomic test for psychiatric medications.
Growth priorities include building a comprehensive Cancer Care Continuum portfolio, expanding Precise MRD for molecular residual disease, and launching the FirstGene 4‑in‑1 prenatal screen in 2026. Myriad highlights collaborations with PATHOMIQ and SOPHiA GENETICS, strong customer satisfaction (Net Promoter Score above 70), and significant R&D investment of $106.8 million in 2025.
The report notes competition from major diagnostic players, dependence on payer reimbursement, evolving FDA, CLIA, EU and UK regulation, and extensive IP and licensing arrangements. As of June 30, 2025, non‑affiliate market value was $494,049,876, and as of February 19, 2026, there were 93,508,165 shares outstanding and about 2,700 employees.
Myriad Genetics reported fourth quarter 2025 revenue of $209.8 million, essentially flat year-over-year, with a GAAP net loss of $7.9 million, or $0.08 per share. On a non-GAAP basis, adjusted EPS was $0.04 and adjusted EBITDA was $14.3 million, reflecting lower operating expenses.
For full-year 2025, revenue was $824.5 million, down 2%, and the company recorded a GAAP net loss of $365.9 million, driven largely by $319.4 million of goodwill and long-lived asset impairments. Cash and cash equivalents were $149.6 million at December 31, 2025. Myriad reaffirmed 2026 guidance, targeting revenue of $860–$880 million, adjusted gross margin of 68–69%, and adjusted EBITDA of $37–$49 million, with Q1 2026 revenue expected between $200 and $203 million.
Myriad Genetics, Inc. received an amended Schedule 13G filing showing that funds associated with Millennium now report a sizable passive stake in its common stock. Integrated Core Strategies (US) LLC reports beneficial ownership of 5,183,588 shares, representing 5.6% of the outstanding common stock.
Affiliates Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander each report beneficial ownership of 6,700,158 shares, or 7.2% of the class, with shared voting and dispositive power. The filing is certified as a passive investment, stating the securities were not acquired to change or influence control of Myriad Genetics.
State Street Corporation filed a Schedule 13G reporting a passive ownership stake in Myriad Genetics, Inc. common stock as of 12/31/2025. State Street reports beneficial ownership of 5,966,567 shares, representing 6.4% of Myriad Genetics’ outstanding common stock.
The filing shows State Street has shared voting power over 5,683,556 shares and shared dispositive power over 5,966,567 shares, with no sole voting or dispositive power. State Street certifies the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Myriad Genetics.